Cyclacel Pharma (NASDAQ: CYCC) adds to gains following earlier volatility trading halt and news over the weekend from AACR ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Momentum Movers Trader Talk

Cyclacel Pharma (CYCC) Halted on LUDPApril 4, 2017 10:25 AM Cyclacel Pharma (CYCC) Continues Monday's Surge Following Preclinical Anti-Cancer Data; Gains Another 40%April 4, 2017 8:13 AM Cyclacel Pharma (CYCC) Halted on LUDPApril 3, 2017 9:57 AM Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic PathwaysApril 2, 2017 1:00 PM